---
title: "Aggressive B‑cell lymphoma with MYC gene cluster amplification: clinicopathological findings in ei"
id: "pubmed-42706110"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42706110"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42706110/"
doi: "10.3760/cma.j.cn112151-20260129-00097"
published_at: "2026-09-08T00:00:00.000Z"
evidence_level: "English Abstract"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Aggressive B‑cell lymphoma with MYC gene cluster amplification: clinicopathological findings in ei
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42706110
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42706110/)
- **DOI:** [10.3760/cma.j.cn112151-20260129-00097](https://doi.org/10.3760%2Fcma.j.cn112151-20260129-00097)
- **Published At:** 2026-09-08T00:00:00.000Z
- **Evidence Rating:** English Abstract
## Executive GIST (TL;DR)
- This study analyzed eight cases of aggressive B‑cell lymphoma (ABCL) with **MYC gene cluster amplification**, collected between 2018 and 2025, including six cases from a single center and two external consultation cases. - Patients were predominantly elderly (median age 71.5 years) and male (6/8). - Clinical presentation among the six in‑house patients was abdominal pain without B symptoms; most were Ann Arbor stage III–IV at diagnosis and five of six had extranodal disease, mainly involving the **gastrointestinal tract** (4/5). - One patient had post‑renal transplant immunosuppression. Initial bone marrow biopsies were negative for lymphoma in all tested in‑house patients. - Histologically, two cases had diffuse large B‑cell lymphoma (DLBCL) morphology; six showed high‑grade features and three had Burkitt‑like morphology. One case was a blastoid variant of mantle cell lymphoma. - Immunophenotyping showed a germinal center B‑cell phenotype in six of seven evaluable cases (6/7). - Fluorescence in situ hybridization (FISH) in the six in‑house cases showed no **bcl‑2** or **bcl‑6** rearrangements. - Chromosomal/array testing identified **11q alterations** in seven of eight cases (five with combined gain/loss and two with 11q gain); one 11q gain case showed no telomeric loss of heterozygosity on chromosomal microarray. - Follow‑up ranged from 5.9 to 55.5 months; five patients were alive at last follow‑up. The authors conclude ABCL with MYC cluster amplification often shows high‑grade morphology with gastrointestinal involvement, a strong association with 11q alteration, and appears to have a favorable prognosis. - Conflict of interest: all authors declared no conflicts. - Specifics of treatment regimens and detailed response data were not reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42706110/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706110%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42706110/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42706110/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42706110/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42706110/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42706110/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706110%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706110%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42706110/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706110/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706110/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42706110/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706110/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42706110/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42706110/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42706110/#conflict-of-interest) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42706110/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42706110/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42706110/#substances) * [ Supplementary concepts ](https://pubmed.ncbi.nlm.nih.gov/42706110/#supplementary-concepts) Title & authors Abstract Conflict of interest statement Publication types MeSH terms Substances Supplementary concepts Zhonghua Bing Li Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Bing+Li+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Bing+Li+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) . 2026 Sep 8;55(9):839-846. doi: 10.3760/cma.j.cn112151-20260129-00097. # [Aggressive B-cell lymphomas with MYC gene cluster amplification: a clinicopathological analysis of eight cases] [Article in Chinese] [Z H Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+ZH&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#full-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [X D Teng](https://pubmed.ncbi.nlm.nih.gov/?term=Teng+XD&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#full-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [M C Zeng](https://pubmed.ncbi.nlm.nih.gov/?term=Zeng+MC&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#full-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [H Cao](https://pubmed.ncbi.nlm.nih.gov/?term=Cao+H&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#full-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [B Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+B&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#full-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.") Affiliations Expand ### Affiliation * 1 Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. * PMID: **42706110** * DOI: [ 10.3760/cma.j.cn112151-20260129-00097 ](https://doi.org/10.3760/cma.j.cn112151-20260129-00097) Item in Clipboard # [Aggressive B-cell lymphomas with MYC gene cluster amplification: a clinicopathological analysis of eight cases] [Article in Chinese] Z H Wang et al. Zhonghua Bing Li Xue Za Zhi. 2026. Show details Display options Display options Format Abstract PubMed PMID Zhonghua Bing Li Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Bing+Li+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Bing+Li+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) . 2026 Sep 8;55(9):839-846. doi: 10.3760/cma.j.cn112151-20260129-00097. ### Authors [Z H Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+ZH&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#short-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [X D Teng](https://pubmed.ncbi.nlm.nih.gov/?term=Teng+XD&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#short-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [M C Zeng](https://pubmed.ncbi.nlm.nih.gov/?term=Zeng+MC&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#short-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [H Cao](https://pubmed.ncbi.nlm.nih.gov/?term=Cao+H&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#short-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China."), [B Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+B&cauthor_id=42706110)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706110/#short-view-affiliation-1 "Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.") ### Affiliation * 1 Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. * PMID: **42706110** * DOI: [ 10.3760/cma.j.cn112151-20260129-00097 ](https://doi.org/10.3760/cma.j.cn112151-20260129-00097) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract in [ English, ](https://pubmed.ncbi.nlm.nih.gov/42706110/#eng-abstract) [ Chinese ](https://pubmed.ncbi.nlm.nih.gov/42706110/#zho-abstract) **Objective:** To investigate the clinicopathological characteristics, molecular genetics, treatments and prognosis of aggressive B-cell lymphomas (ABCL) with MYC gene cluster amplification. **Methods:** Eight cases of ABCL with MYC gene cluster amplification were collected, including 6 cases from the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China and 2 consultation cases from outside hospitals. The histomorphology, immunohistochemical profiles, and molecular genetic characteristics were analyzed. Clinical follow-up and literature review were also conducted. **Results:** Among the eight patients, six were male and two were female, with an age 71.5 (61.7, 74.2) years. All six in-house patients presented with abdominal pain at onset, without B symptoms. Most cases were classified as Ann Arbor stage Ⅲ-Ⅳ. Extranodal involvement occurred in 5 of the 6 in-house cases, primarily affecting the gastrointestinal tract (4/5). All initial bone marrow biopsies showed no evidence of lymphoma. One patient had a history of immunosuppression following renal transplantation. Two cases exhibited diffuse large B-cell lymphoma (DLBCL) morphology. The other six showed high-grade features, while three of them showed Burkitt lymphoma-like morphology. Except for one case of blastoid variant mantle cell lymphoma, the remaining six cases (6/7) displayed a germinal center B-cell phenotype. None of the in-house cases harbored bcl-2 or bcl-6 rearrangements as shown by fluorescence in situ hybridization. 11q alterations were identified in all but one consultation case, including gain/loss type in five cases and 11q gain in two. 11q telomere loss of heterozygosity by chromosomal microarray analysis was not detected in one of the two cases with 11q gain that was subject to the test. The duration of follow-up ranged from 5.9 to 55.5 months, with 5 patients alive at the end of the study. **Conclusions:** ABCL with MYC gene cluster amplification often presents high-grade morphology and gastrointestinal involvement, which strongly suggests the alteration of 11q. It seems to have a favorable prognosis. **目的：** 探讨伴有MYC基因簇状扩增的侵袭性B细胞淋巴瘤（aggressive B-cell lymphoma，ABCL）的临床病理学特征、分子遗传学改变及预后。 **方法：** 收集2018年7月至2025年8月浙江大学医学院附属第一医院诊断伴MYC基因簇状扩增的ABCL病例8例，其中本院6例，外院会诊2例。分析其组织学形态、免疫组织化学及分子遗传学特征，并对该组病例进行随访及文献复习。 **结果：** 8例患者中男性6例，女性2例，年龄71.5（61.7，74.2）岁。6例本院患者发病时均表现为腹痛，无B症状，Ann Arbor分期以Ⅲ~Ⅳ期为主，5例患者出现结外侵犯，最常累及胃肠道（4/5），初诊骨髓活检均未见淋巴瘤累及。1例患者有肾移植的免疫功能低下史。2例患者表现为弥漫性大B细胞淋巴瘤（DLBCL）形态，6例具有高级别形态，其中3例出现伯基特淋巴瘤特征。除1例套细胞淋巴瘤母细胞变异型，6例（6/7）具有生发中心B细胞表型。本院6例病例中bcl-2、bcl-6经荧光原位杂交检测均为重排阴性。1例会诊病例无法获得样本，7例存在11q改变，包括5例11q获得/缺失和2例11q获得病例。1例11q获得病例经染色体基因芯片检测验证无端粒杂合性丢失。6例本院患者随访5.9~55.5个月，5例患者存活。 **结论：** MYC基因簇状扩增的ABCL常具有高级别形态并常常伴有胃肠道的累及，此类侵袭性B细胞淋巴瘤高度提示11q存在异常，预后较好。. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement 所有作者声明无利益冲突 ## Publication types * English Abstract Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22English+Abstract%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=English+Abstract) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) ## MeSH terms * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Antineoplastic Combined Chemotherapy Protocols / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Burkitt Lymphoma / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Burkitt+Lymphoma%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Burkitt+Lymphoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Burkitt Lymphoma / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Burkitt+Lymphoma%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Burkitt+Lymphoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Burkitt Lymphoma / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Burkitt+Lymphoma%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Burkitt+Lymphoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Burkitt Lymphoma / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Burkitt+Lymphoma%2Fpathology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Burkitt+Lymphoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Cyclophosphamide / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cyclophosphamide%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cyclophosphamide) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * DNA-Binding Proteins / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22DNA-Binding+Proteins%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=DNA-Binding+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Doxorubicin / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Doxorubicin%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Doxorubicin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Follow-Up Studies Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Follow-Up+Studies%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Follow-Up+Studies) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Gastrointestinal Neoplasms / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gastrointestinal+Neoplasms%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gastrointestinal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Gastrointestinal Neoplasms / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gastrointestinal+Neoplasms%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gastrointestinal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Gastrointestinal Neoplasms / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gastrointestinal+Neoplasms%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gastrointestinal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Gastrointestinal Neoplasms / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gastrointestinal+Neoplasms%2Fpathology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gastrointestinal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Gene Amplification* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gene+Amplification%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gene+Amplification) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Genes, myc* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Genes%2C+myc%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Genes%2C+myc) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706110/) * Lymphoma, Large B-Cell, Diffuse* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Large+B-Cell%2C+Diffuse%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in
## Related Clinical Research

- [Doxorubicin plus Paclitaxel: Repurposed combination with potential activity in diffuse large B‑cel](https://medichelpline.com/clinical-feed/pubmed-42235267.md) (DOI: 10.1016/j.compbiomed.2026.111781)
- [Erianin and Doxorubicin in Diffuse Large B-Cell Lymphoma: Study Overview on GSDMD, PI3K/AKT, and S](https://medichelpline.com/clinical-feed/pubmed-40830921.md) (DOI: 10.1097/CM9.0000000000003634)
- [GAA as a Prognostic Biomarker and Therapeutic Target in Angioimmunoblastic T‑cell Lymphoma — Full](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-multi-omics-analysis-identifies-gaa-as-an-independent-poor-prognostic-biomarker.md)
- [Surface Chemistry and pH Control Structural Dynamics and Drug Binding in PETIM and PAMAM Dendrimers](https://medichelpline.com/clinical-feed/biorxiv-18-surface-functionality-and-ph-govern-structural-dynamics-and-drug-binding-in.md)
- [Doxorubicin Hydrochloride Injectable, Liposomal (Zydus) Updated](https://medichelpline.com/clinical-feed/dailymed-updates-8-doxorubicin-hydrochloride-injectable-liposomal-zydus-pharmaceuticals-usa-inc-.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.